Number of participants experiencing disability progression · primary progressive multiple sclerosis
Ocrelizumab may leads to lower number of participants experiencing disability progression compared with placebo (low certainty).
1 finding from 1 review
Number of participants with any adverse events · primary progressive multiple sclerosis
Ocrelizumab probably leads to higher number of participants with any adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Subjective memory measures ‐ intermediate EMQ, MSNQ, CFQ, MFQa · people with multiple sclerosis
1 finding from 1 review
Intervention not reported
Objective verbal memory measures ‐ intermediate CVLT, AVLT, HVLT, VLT, SRT, MUSICa · people with multiple sclerosis
1 finding from 1 review
Intervention not reported
Objective visual memory measures ‐ intermediate BVMT‐R, SPART, CMT, ROCF · people with multiple sclerosis
1 finding from 1 review
Intervention not reported
Objective working memory measures ‐ intermediate PASAT, WAIS · people with multiple sclerosis
1 finding from 1 review
Intervention not reported
Informating processing ‐ intermediate SDMT · people with multiple sclerosis
1 finding from 1 review
Intervention not reported
Quality of life ‐ intermediateMSIS, MSQOL, SF‐36, SF‐12, SWLS, EQ‐5D‐5La · people with multiple sclerosis
1 finding from 1 review
Intervention not reported
Acitivities of daily living ‐ intermediateEADLa · people with multiple sclerosis
1 finding from 1 review
Relapse · people with multiple sclerosis
It is very uncertain whether siponimod changes number of participants with relapses at 6 months compared with placebo (very low certainty).
1 finding from 1 review
Disability worsening · people with multiple sclerosis
Siponimod may leads to lower participants with disability worsening at 6 months compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with multiple sclerosis
Siponimod showed no clear difference in number of participants who withdrew due to AEs at 6 months compared with placebo (low certainty).
1 finding from 1 review
Annualised relapse rate · people with multiple sclerosis
Siponimod may leads to lower annualised relapse rate compared with placebo (low certainty).
1 finding from 1 review
Mean number of gadolinium‐enhancing lesions on T1‐weighted brain MRI image at 6 months · people with multiple sclerosis
It is very uncertain whether siponimod changes mean number of gadolinium‐enhancing lesions on T1‐weighted brain MRI… compared with placebo (very low certainty).
1 finding from 1 review
Mean number of new lesions or enlarged pre‐existing lesions on T2‐weighted brain MRI images at 6 months · people with multiple sclerosis
Siponimod may leads to lower mean number of new lesions or enlarged pre‐existing lesions on… compared with placebo (low certainty).
1 finding from 1 review
SAEs · people with multiple sclerosis
Siponimod showed no clear difference in number of participants with at least one SAE at 6 months compared with placebo (low certainty).
1 finding from 1 review
Comparison intervention · relapsing multiple sclerosis
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Quality of life · primary progressive multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Common infections measured by clinical assessment over 28 months · primary progressive multiple sclerosis
Rituximab as 'first choice' showed no clear difference in common infections measured by clinical assessment over 28 months compared with placebo (low certainty).
1 finding from 1 review
Cancer · primary progressive multiple sclerosis
Rituximab as 'first choice' showed no clear difference in cancer measured by clinical assessment over 28 months compared with placebo (low certainty).
1 finding from 1 review